Skinvisible, Inc. (OTCBB: SKVI) RHEI Agreement Penetrates New Markets for SKVI

Skinvisible, Inc. (OTCBB: SKVI)

Skinvisible, Inc. (OTCBB: SKVI) makes money by licensing its agreement.  The RHEI Pharmaceuticals HK Ltd. is a Hong Kong-based pharmaceutical company and a subsidiary of Luxembourg-based Leeward Ventures SICAR SCA.  An exclusive licensing agreement is  for the commercial/institutional rights for DermSafe(R) Hand Sanitizer for Europe and China for three skincare products.

These two new agreements with RHEI represent $1.5 million in licensing fees.  In addition on-going royalties will be received on product sales for Skinvisible.

RHEI will leverage its affiliate BeoCare Group, a leading medical consumables manufacturer with facilities in the United States, Europe and China, to provide access to the institutional / healthcare markets through its established network of multi-national clients. Additionally, RHEI will also sell to its affiliate, Senior Assist NV, one of the largest assisted living providers in Belgium, with a chain of thirty-three seniors’ homes.

RHEI is they are in a prime position to capture significant market share and revenue from these products. The annual institutional spending on incontinence products in the United States alone reaches $32+ million. RHEI is in an ideal position to penetrate this market with their regulatory and commercialization experience and established client list.

RHEI Pharmaceuticals Ltd. License Agreement

RHEI Pharmaceuticals Ltd. (RHEI) is a global pharmaceutical business development firm, with special focus on bringing core medicines from the U.S., Europe and Japan into the fast-growing South-East Asian marketplace. This is a Hong Kong-based pharmaceutical company and a subsidiary of the Luxembourg-based Leeward Ventures SICAR SCA. They are experts in business development, regulatory approval and clinical development and have a management team that combines a Western approach to pharmaceuticals with a long experience in Europe, North America and South-East Asia. They use their development capabilities and network of preferred commercial partners to help other pharmaceutical companies introduce their products into specific niche markets, such as the European institutional health care market and the Chinese hospital market. RHEI is headquartered in Hong Kong and has operations in Belgium, the U.S. and China.

Skinvisible completed an exclusive license agreement granting RHEI, the exclusive rights to three Skinvisible formulations developed using its patented Invisicare polymer delivery system in mid July 2010.

The agreement specifies exclusivity for the products for the institutional / healthcare market for:

  • An adult incontinence cream
  • Skin barrier cream
  • Super moisturizer

Upfront license fees for the territories of Europe and China and milestone payments based on approvals and launch dates for the United States are included. In addition, Skinvisible will receive royalties on sales of the products. RHEI will be responsible for regulatory filings, manufacturing and commercialization of the products.

Skinvisible, Inc. (OTCBB: SKVI)

6320 S. Sandhill Road, Suite 10
Las Vegas, Nevada, 89120 U.S.A.
Phone: 702.433.7154
Fax: 702.433.7192
Phone: 801.485.7978
Fax: 801.466.6877

About Invisicare: Invisicare is Skinvisible’s patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, license fees, and royalties for the life of the patent. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare.

Forward Looking Statements: Certain statements, other than purely historical information, including estimates, projections, statements relating to SKVI business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. SKVI’s ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in other filings with the SEC.

StockGuru is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru LLC entered into an investor relations consulting and market awareness contract on July 12, 2010. The company has agreed to pay us five thousand dollars per month in cash for the period of six months, totaling thirty thousand USD. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. To further clarify, we will not be buying or selling shares for the period of July 12, 2010 through January 12, 2011. We hold no shares and will not be receiving further compensation that is share related during this period. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.